NASDAQ: BEAMBeam Therapeutics Inc Stock
$19.93+0.22 (+1.12%)
Updated Apr 30, 2025
BEAM Price
$19.93
Fair Value Price
N/A
Market Cap
$1.67B
52 Week Low
$13.53
52 Week High
$35.25
P/E
-4.35x
P/B
2.27x
P/S
32.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$63.52M
Earnings
-$376.74M
Gross Margin
100%
Operating Margin
-593.06%
Profit Margin
-593.1%
Debt to Equity
0.51
Operating Cash Flow
-$347M
Beta
1.9
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BEAM Overview
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BEAM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BEAM
Ranked#256 of 462
Ranked#256 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important BEAM news, forecast changes, insider trades & much more!
BEAM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BEAM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BEAM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BEAM is good value based on its book value relative to its share price (2.27x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
BEAM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BEAM due diligence checks available for Premium users.
Valuation
BEAM fair value
Fair Value of BEAM stock based on Discounted Cash Flow (DCF)
Price
$19.93
Fair Value
-$24.00
Undervalued by
183.05%
BEAM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BEAM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.35x
Industry
-162.28x
Market
29.18x
BEAM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.27x
Industry
4.45x
BEAM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BEAM's financial health
Profit margin
Revenue
$30.1M
Net Income
-$90.4M
Profit Margin
-300.5%
BEAM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BEAM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$370.3M
Debt to equity
0.51
BEAM's short-term assets ($878.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BEAM's short-term assets ($878.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BEAM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BEAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$76.4M
Investing
$126.3M
Financing
$3.4M
BEAM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BEAM vs Biotech Stocks
Beam Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.